T1	Chemical	19 30	selumetinib
T2	Chemical	33 40	AZD6244
T3	Chemical	43 54	ARRY-142866
T4	Gene_or_protein	61 77	MEK1/2 inhibitor
T5	Chemical	59 79	a MEK1/2 inhibitor ,
T6	Chemical	83 112	combination with cetuximab in
T7	Disease	113 140	refractory solid tumors and
T8	Disease	146 172	mutant colorectal cancer .
R1	isEquivalentTo	Arg1:T1	Arg2:T2
R2	influences	Arg1:T1	Arg2:T3
R3	treats	Arg1:T1	Arg2:T4
R4	treats	Arg1:T1	Arg2:T5
R5	treats	Arg1:T1	Arg2:T6
R6	treats	Arg1:T1	Arg2:T7
R7	treats	Arg1:T1	Arg2:T8
R8	isEquivalentTo	Arg1:T2	Arg2:T1
R9	isEquivalentTo	Arg1:T2	Arg2:T3
R10	influences	Arg1:T2	Arg2:T5
R11	treats	Arg1:T2	Arg2:T6
R12	treats	Arg1:T2	Arg2:T7
R13	treats	Arg1:T2	Arg2:T8
R14	isEquivalentTo	Arg1:T3	Arg2:T1
R15	isEquivalentTo	Arg1:T3	Arg2:T2
R16	isEquivalentTo	Arg1:T3	Arg2:T4
R17	isEquivalentTo	Arg1:T3	Arg2:T5
R18	treats	Arg1:T3	Arg2:T7
R19	treats	Arg1:T3	Arg2:T8
R20	isEquivalentTo	Arg1:T4	Arg2:T1
R21	influences	Arg1:T4	Arg2:T3
R22	decreases	Arg1:T4	Arg2:T5
R23	treats	Arg1:T4	Arg2:T6
R24	treats	Arg1:T4	Arg2:T7
R25	treats	Arg1:T4	Arg2:T8
R26	isEquivalentTo	Arg1:T5	Arg2:T1
R27	influences	Arg1:T5	Arg2:T2
R28	influences	Arg1:T5	Arg2:T3
R29	decreases	Arg1:T5	Arg2:T4
R30	treats	Arg1:T5	Arg2:T6
R31	treats	Arg1:T5	Arg2:T7
R32	treats	Arg1:T5	Arg2:T8
R33	isEquivalentTo	Arg1:T6	Arg2:T1
R34	influences	Arg1:T6	Arg2:T2
R35	influences	Arg1:T6	Arg2:T3
R36	influences	Arg1:T6	Arg2:T4
R37	influences	Arg1:T6	Arg2:T5
R38	treats	Arg1:T6	Arg2:T7
R39	treats	Arg1:T6	Arg2:T8
R40	isEquivalentTo	Arg1:T7	Arg2:T1
R41	influences	Arg1:T7	Arg2:T2
R42	influences	Arg1:T7	Arg2:T3
R43	isAssociatedWith	Arg1:T7	Arg2:T4
R44	isAssociatedWith	Arg1:T7	Arg2:T6
R45	treats	Arg1:T7	Arg2:T8
R46	isAssociatedWith	Arg1:T8	Arg2:T1
R47	isAssociatedWith	Arg1:T8	Arg2:T2
R48	isAssociatedWith	Arg1:T8	Arg2:T3
R49	isAssociatedWith	Arg1:T8	Arg2:T4
R50	isAssociatedWith	Arg1:T8	Arg2:T5
R51	isAssociatedWith	Arg1:T8	Arg2:T6
R52	isAssociatedWith	Arg1:T8	Arg2:T7
